Background & Aims. Activation of MYC and CTNNB1 (encoding b-catenin) can co-occur in liver cancer, but how these oncogenes cooperate in tumorigenesis remains unclear.
Introduction
Liver cancers, among which hepatocellular carcinoma (HCC) is the predominant form, are the second cause of cancer-related mortality worldwide (1) . Heterogeneity in genomic alterations in HCCs, as revealed by recent large-scale genome sequencing efforts, renders the understanding of driving molecular events and the design of targeted therapeutic strategies very challenging, with HCC patients still having limited therapeutic options (1, 2) .
One of the most frequently altered pathways in HCC is WNT/b-catenin signaling (1) (2) (3) . In this pathway, also known as "canonical" WNT signaling, the exposure of cells to WNT ligands leads to stabilization of the transcriptional coactivator b-catenin, which is then free to translocate to the nucleus and activate target genes in association with DNA-binding factors of the TCF family (4) . bcatenin turnover is regulated by the so-called "destruction complex", a cytoplasmic assembly that includes -among others -Axin1, APC, the ubiquitin ligase b-TrCP and the kinases CK1a/d and GSK3a/b. In the absence of Wnt ligands, these kinases phosphorylate b-catenin at several sites, creating a discrete phospho-degron motif that acts as a docking site for b-TrCP, thus triggering ubiquitination and proteasome-mediated degradation of b-catenin (4) . Activation of the WNT/βcatenin pathway in cancer can occur either via enhanced exposure to WNT ligands, or through genetic lesions in its core components: the latter include loss of APC, most frequent in colorectal cancer (4) , or activating mutations in the b-catenin gene CTNNB1, as commonly observed in HCC (1) (2) (3) .
The MYC proto-oncogene is one of the transcriptional targets of b-catenin/TCF, and functions as a key downstream effector of WNT/b-catenin signaling in several tissues, such as the small intestine, T cells and lung (5) (6) (7) (8) . In the liver, however, this epistatic relationship may not hold true:
in particular, APC loss and the consequent activation of b-catenin do not induce Myc expression (9) and Myc deletion does not suppress the effects of APC loss on either hepatocyte proliferation (10) or liver zonation (11) . Moreover, there are indications that the two pathways can be independently activated and cooperate in tumorigenesis (12) . In particular, MYC amplification and CTNNB1 mutations showed a tendency toward co-occurrence in either adult HCC or aggressive childhood hepatoblastoma (3, 5, 13) , and MYC-driven HCC in experimental mouse models frequently acquired activating mutations in Ctnnb1 (5, 14, 15) .
In order to unravel the functional cross-talk between MYC and WNT/b-catenin signaling in liver tumorigenesis, we generated a new mouse model allowing conditional activation of MYC and b-catenin in hepatocytes. This model demonstrated a strong cooperativity between the two oncogenes in promoting liver tumorigenesis. Our data indicate that this cooperation occurs mainly through unrestrained proliferation of liver cells, and requires activation of the transcriptional co-factors Yap and Taz.
Materials and Methods

Mice
Alb-CreER T2 mice (termed SA-Cre-ERT2 in the original publication (16) ) were a kind gift from Pierre Chambon, Ctnnb1 DEx3 mice were a kind gift from Makoto Taketo (17) , Taz f/f mice (18) were a kind gift from Stefano Piccolo, Apc f/f (19) mice were a kind gift of Eduard Battle, R26-lsl-CAG-MYC-ires-hCD2* (20) mice were purchased from Jackson Laboratory (Stock No: 020458), R26-lsl-5 EYFP mice were purchased from Jackson Laboratory (Stock No: 006148) and backcrossed into the C57BL/6 background, and Yap f/f mice were purchased from the KOMP Knockout mouse project (https://www.komp.org). For tumor-free survival analysis Alb-CreER T2 ;b-cat Ex3 ;R26-lslMYC mice were monitored 3 times per week and sacrificed when showing abdominal enlargement, indicative of hepatomegaly due to tumor formation. The same procedure was applied to b-cat Ex3 ;R26-lslMYC mice injected at 6-8 weeks of age by tail vein injection with low-titer (10 9 ) AAV8-TBG-CRE particles (University of Pennsylvania Vector Core, #AV-8-PV1091). For short-term liver-specific activation of the various alleles, high-titer (10 11 ) AAV8-TBG-CRE particles were given to 6-to 8-week-old mice, and the mice sacrificed after 2, 4, or 8 days, as specified in the text or figures. Tumor nodules or liver parenchyma were dissected and either processed freshly, or frozen and stored at -80°C until further analysis. CD1-nude mice (purchased from Charles River Laboratories) were injected subcutaneously with 3*10 6 3T9 MycER;S33Y cells, and provided with food containing 400 ppm/kg Tamoxifen (Envigo, #TD.55125.I) and/or drinking water with 2 mg/ml doxycyline hydrate (Sigma-Aldrich, #D9891-100G), as indicated in the text. Mice were monitored 3 times per week and Additional Methods can be found in Supplementary Material and Methods.
Results
MYC and b-catenin cooperate in liver tumorigenesis
In line with previous observations (21) analysis of the TCGA database showed that MYC amplification and CTNNB1 mutations co occur in a fraction of human HCCs (Supplementary Figure   1A ) (2, 3) . To model this scenario, we took advantage of the CRE-activated alleles R26-lsl-CAG-MYC-ires-hCD2* (hereafter R26-lslMYC) (20) and Ctnnb1 DEx3 (hereafter β-cat Ex3 ) (17) (Supplementary Figure 1B) . Recombination of the β-cat Ex3 allele leads to loss of residues 14-89, spanning the phospho-degron of mouse β-catenin, thus mimicking the cancer-associated mutations observed in the human gene. To circumvent the known lethal effects of β-catenin activation in the whole liver (22) , we sought to obtain a sporadic activation of our alleles in a minority of the hepatocytes, which was achieved by two complementary means: (i.) exploiting the basal leakiness of the CreER T2 fusion protein in the absence of its pharmacological activator, and (ii.) infection with low titer CRE-expressing Adeno-Associated viral (AAV) particles.
The Alb-CreER T2 transgene drives constitutive expression of the CreER T2 fusion protein in the liver, allowing controlled post-translational activation of the recombinase by exposure of the animals to Tamoxifen (TAM) (16) . CreER T2 can occasionally show leakiness (23) , causing sporadic recombination events: indeed, even if never exposed to TAM, compound Alb-CreER T2 ;R26-lslMYC mice developed highly penetrant, gender-independent multi-nodal liver tumors, with a median survival of 6 months ( Figure 1A , Supplementary Figure 2A -B). Activation of the β-cat Ex3 allele had no effect on its own, as previously reported (22) , but significantly accelerated tumorigenesis when combined with R26-lslMYC ( Figure 1A ; supplementary Figure 2A ). As expected, the resulting tumors expressed MYC at high levels, the associated hCD2 reporter, as well as the shorter form of βcatenin encoded by the recombined β-cat Ex3 allele ( Figure 1B ; supplementary Figure 1B , 2C). We further assessed the expression of known MYC-and β-catenin-activated genes, confirming the activation of the two oncoproteins (Supplementary Figure 2D , E). The tumors also showed reduced expression of markers typically associated with differentiated hepatocytes (e. g. Ck-18, Albumin, and Hnf-4a) and increased expression of fetal liver markers (e. g. Afp; Supplementary Figure 2F ). Finally, pathological analysis revealed no major differences between MYC-only and MYC/β-catenin tumors, both resembling human HCC with a trabecular pattern ( Figure 1C ; see Supplementary Table 1 for a detailed pathological description). We will thus generally refer to these tumors as mouse hepatocellular carcinomas (mHCCs).
As a second approach to jointly activate MYC and b-catenin in hepatocytes, b-cat Ex3 ;R26-lslMYC and control mice were injected with recombinant AAV8-TBG-CRE particles, which show a high tropism for liver cells and express CRE recombinase under control of the hepatocyte-specific TBG promoter (24) . This system can be used to achieve either sporadic (~5-10% of the cells) or almost complete (>90%) infection of hepatocytes, as measured by CRE-induced activation of the R26-lsl-EYFP reporter allele 4 days after injection of 10 9 (low titer) or 10 11 (high titer) particles (Supplementary Figure 3A) . When infected with AAV8-TBG-CRE at low titer, b-cat Ex3 ;R26-lslMYC mice developed tumors that resembled those arising in Alb-CreER T2 ;b-cat Ex3 ;R26-lslMYC animals, albeit with longer latency (Supplementary Figure 3B , C; Supplementary Table1) -owing most likely to activation of the oncogenes at a later stage of liver development.
Finally, as an alternative means to activate the WNT/β-catenin pathway, we used a conditional knockout allele of APC (19) , bred this to homozygosity (Apc f/f ) in combination with Alb-CreER T2 and R26-lslMYC, and monitored the mice over time in the absence of TAM: as observed above with activation of β-cat Ex3 , deletion of APC had no effect on its own, but accelerated tumorigenesis in the presence R26-lslMYC (Supplementary Figure 2G ). Altogether, our data show that oncogenic activation of MYC and WNT/β-catenin signaling cooperate in liver tumorigenesis.
We next wondered whether the cooperation between MYC and β-catenin is peculiar to hepatocytes or may be recapitulated in other cells. To address this question, we infected 3T9 MycER fibroblasts, which constitutively express a MycER T2 chimaera (25) , with a doxycycline-inducible lentiviral vector encoding a 6xMyc-tagged S33Y-mutant version of β-catenin resistant to GSK3βinduced phosphorylation and proteasomal degradation (hereafter β-cat S33Y ) (26) . Immunoblot and RT-qPCR analysis of 3T9 MycER;S33Y cells confirmed the induction of β-cat S33Y by doxycycline, as well as an increase in MycER levels -most likely due to stabilization of the protein -upon 4hydroxytamoxifen (4-OHT) treatment (Supplementary Figure 4A ). Importantly, β-catenin-and MYC-activated genes were induced upon doxycycline and 4-OHT treatment, respectively, indicating that the two transcription factors were active (Supplementary Figure 4B Figure 4D ); most importantly, however, co-activation of MycER T2 and β-cat S33Y allowed colony formation in methylcellulose, indicating that the cells had acquired the capacity to proliferate in suspension ( Figure 1D ). 3T9 MycER;S33Y cells were then implanted subcutaneously in CD1-nude mice: in this setting, combined treatment of the animals with Doxycycline and Tamoxifen, but neither alone, led to tumor formation ( Figure 1E ). Thus, co-activation of MYC and β-catenin supports the malignant transformation of immortalized mouse fibroblasts. Altogether, the above results demonstrate that MYC and WNT/β-catenin signaling cooperate in cellular transformation. In particular, we showed that the aberrant activation of MYC in the mouse liver promoted the development of undifferentiated hepatocellular carcinomas, whose latency was strongly reduced upon either activation of β-catenin, or deletion of APC. Most importantly, MycER and b-cat S33Y also cooperated in the transformation of fibroblasts in vitro. Thus, besides its recently reported impact on immune surveillance (21) , β-catenin also cooperates with MYC through cellautonomous mechanisms.
Concomitant activation of Myc and b-catenin induces of a pro-proliferative, Yap/Taz-related, transcriptional signature
Considering the prevalence of secondary transcriptional responses in established Myc-driven mHCCs (27) , we sought to profile the short-term effects of MYC and b-cat Ex3 activation in hepatocytes. In this regard, short-term activation of CreER T2 in young Alb-CreER T2 ;b-cat Ex3 ;R26-lslMYC mice did not provide a clean model, owing to the possible confounding effects of pre-existing tumoral lesions. In order to circumvent this caveat, we focused on the short-term activation of R26-lslMYC and/or b-cat Ex3 with injection of high-titer AAV8-TBG-CRE particles. RNA-seq profiles were established 4 days after infection, a time at which both MYC and β-cat Ex3 were expressed in hepatocytes, showing clear nuclear localization and transcriptional activity (Supplementary Figure   5A -E). Of note, activation of β-cat Ex3 did not increase Myc mRNA levels (Supplementary Figure 5C ), indicating that Myc is not regulated by WNT/b-catenin in hepatocytes, as previously reported (9, 10) .
Activation of b-cat Ex3 alone induced limited transcriptional changes relative to AAV-infected wild-type livers, with only 98 differentially expressed genes (DEGs), while MYC regulated almost 3000 genes, either up or down (Figure 2A ). This MYC-driven transcriptional program was largely unchanged upon co-activation of b-cat Ex3 (Figure 2B , Supplementary Figure 6A ). Gene ontology analysis showed that MYC, either alone or in combination with b-catenin, elicited not only MYC-, but also E2F-, mTOR-and WNT/b-catenin-associated gene signatures: the latter was mobilized by either β-cat Ex3 or MYC alone, but responded with higher statistical significance in presence of both oncogenes ( Figure 2C , Supplementary Table 2 ). In line with these findings, direct comparison between MYC/b-cat Ex3 and MYC-overexpressing livers yielded only 37 DEGs (33 up and 4 down, Supplementary Figure 6A ), comprising canonical WNT/b-catenin targets (Axin2, Lgr5, Notum, Sp5, Tbx3 and Tcf7; Supplementary Table 2 ).
To address whether the cooperation between MYC and b-cat Ex3 in liver tumorigenesis may be associated with more subtle transcriptional changes, we focused on genes that were induced both by MYC and MYC/b-cat Ex3 overexpression, but whose fold change in expression relative to wild type livers was at least 1.5 times higher in MYC/b-cat Ex3 compared to MYC ( Figure 2D ): this led to the identification of a group of 125 genes that we will refer to as the "MYC/b-catenin signature". Importantly, these genes were also induced in advanced mHCC tumors relative to wild type livers, and with a higher magnitude in MYC/b-cat Ex3 than in MYC-only tumors. Gene ontology analysis revealed that the MYC/b-catenin signature enriched -among others -for Yap/Taz transcriptional targets ( Supplementary Table 3 ). Moreover, 59 out of 125 genes (~45%) in our MYC/b-catenin signature (as opposed to ~14% of all active genes) scored as direct Yap targets by chromatin immunoprecipitation (28, 29) (Biagioni et al., manuscript in preparation) ( Supplementary Table 3 ). Altogether our data support a model in which β-catenin promotes the stabilization of the Yap and Taz proteins, as previously reported (30) , thus enhancing transcription of a subset of common Yap/Taz and MYC targets involved in promoting cell-cycle progression (31) . In the liver, as opposed to fibroblasts, MYC also contributed to the up-regulation of Yap/Taz: while this effect remains to be explained at the mechanistic level, it further emphasizes the importance of Yap/Taz in Mycdependent transformation (31) .
High expression of the MYC/b-catenin signature correlates with worst prognosis in HCC patients.
Having defined a distinct MYC/b-catenin signature in mouse liver, we went on to address its significance in human cancer. In either of two independent HCC datasets (TCGA and LCI/FUDAN, see Supplementary Material & Methods), querying for the enrichment of our MYC/b-catenin signature allowed us to identify a distinct subgroup of patients whose tumors expressed high levels of the corresponding mRNAs ( Figure 4A, B ). In agreement with data from our mouse model, most of these patients also showed high expression of the MYC (32, 33), WNT (32, 33) and Yap/Taz (28) transcriptional signatures ( Figure 4A Figure 10D ). We surmise that Yap/Taz-null cells are counter-selected during tumorigenesis, pointing to an essential function of these proteins in MYC/b-cat Ex3 -driven tumors. To corroborate this interpretation, we grew tumor cells in vitro and treated them with 4-OHT to activate (35) . However, this mechanism was not verified in our model: as judged by TUNEL staining, MYC-induced apoptosis was not decreased, but rather increased in the presence of b-cat Ex3 (Supplementary Figures 12A, B ), most likely associated with the hyper-proliferative response.
Altogether our results support an essential, but mutually redundant role for Yap/Taz as downstream effectors of b-cat Ex3 , driving the cooperation with MYC through activation of a set of genes, which in turn promote proliferation in hepatocytes.
Discussion
In this study, we describe a mouse model that recapitulates the co-activation of MYC and WNT/b-catenin observed in a fraction of human HCCs (2, 3) . While confirming that Myc is not a downstream transcriptional target of WNT/b-catenin in the liver (9) , as opposed to other tissues (5- In order to address the mechanisms underlying the cooperativity of MYC and b-catenin, we profiled gene expression shortly after their co-activation in hepatocytes. Our data did not reveal any major interference between MYC-and /b-catenin-regulated transcriptional programs, but unveiled the existence of a discrete MYC/b-catenin signature of 125 genes, which were more induced upon co-activation of both oncogenes and mainly encoded products involved in cell cycle control and proliferation. Strikingly, this signature enriched for genes previously reported to be under the direct control of the transcriptional co-activators Yap/Taz. In subsequent experiments, we showed that Yap and Taz were induced upon short-term activation of MYC and b-cat Ex3 in the liver, and were essential for the proliferative response of hepatocytes. In line with these observations, Yap/Taz were also abundant in MYC/b-cat Ex3 tumors and were required for the growth and survival of tumor cells.
Our findings on the role of Yap/Taz as effectors in the cooperative action of MYC and b-catenin connects two apparently unlinked regulatory cross-talks, including (i.) the activation of Yap/Taz by WNT/b-catenin signaling (18, 30, 36) and (ii.) the cooperation between Myc and Yap in supporting either cell proliferation in serum-stimulated fibroblasts, or tumorigenesis in the liver (31) . First, besides signaling cues such as the Hippo pathway, mechanotransduction (37) or a non-canonical (bcatenin-independent) WNT pathway (38) , Yap/Taz have been linked to WNT/b-catenin signaling (18, 30, 36) . Taz in particular was shown to be recruited to -and degraded by the destruction complex in a b-catenin-dependent manner (30) . Moreover, Yap/Taz were stabilized and activated following either knock-out of Apc in mouse tissues and human cell lines (18, 30, 36) , or expression of the stable b-catenin mutant b-cat Ex3 in the small intestine (36) . It is noteworthy here that additional contextdependent mechanisms may be involved in the aforementioned effects: in fibroblasts, activation of b-cat S33Y (but not Myc) induced accumulation of Taz; in hepatocytes, instead, either b-cat Ex3 or Myc alone caused mild increases in Yap/Taz levels, which were markedly enhanced by the co-activation of both oncogenes. Altogether, while the molecular basis for these additional effects remains to be addressed, the above findings establish Yap/Taz as downstream effectors of WNT/b-catenin signaling. As a second connection, Yap was shown to cooperate with Myc in supporting either cell proliferation or tumorigenesis, and did so through the joint activation of a subset of proliferationassociated genes (31) . Indeed, almost half of the genes included in our MYC/b-catenin signature were independently identified as direct targets of Yap, and were induced upon co-activation of MYC and Yap in the liver. Altogether, we conclude that Yap/Taz link WNT/b-catenin activation to a MYCregulated proliferative program, underlying the cooperativity between these two oncogenic pathways.
While the involvement of MYC, WNT/b-catenin and Yap/Taz in liver tumorigenesis was amply documented (3, 13, 31, (39) (40) (41) (42) (43) , their mutual interplay -if any -remained to be unraveled. Toward this aim, we re-analyzed gene expression profiles from two independent patient cohorts, and observed that the MYC/b-catenin signature identified in our work was enriched in a subset of HCC patients, in which it correlated with worse prognosis.
In recent years, Yap/Taz have emerged as key player in tumorigenesis in different tissues (37) , and several approaches for the inhibition of their expression and/or activity have been proposed as potential therapeutic options (44) . Our results add a new element in this regard, indicating that a therapeutic strategy aimed at tackling Yap/Taz may be particularly effective in tumors with aberrant activation of MYC and WNT/b-catenin. Moreover, targeting Yap and Taz may be therapeutically safe, given that their deletion showed limited short-term effects in normal tissues, including the liver (34, 45) . In this regard, an attractive class of molecules -already in use in the clinic -are statins, which have been demonstrated to (i) suppress Yap/Taz function by impairing their nuclear import and promoting their degradation (46, 47) , (ii) reducing Taz-dependent HCC proliferation (48) and (iii) decreasing the risk of cancer mortality, in particular for HCC (49, 50) .
Altogether, our work in mice has revealed a novel functional interplay between MYC, WNT/bcatenin and Yap/Taz in liver tumorigenesis. Most importantly, these interactions hold true in human HCC, with important prognostic implications. Future work will address whether targeting these pathways may hold personalized therapeutic potential in patients whose tumors show co-activation of these pathways. 
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Figure Legends
Western Blot
Liver Table 5 ). Chemiluminescence was detected using a CCD camera (ChemiDoc XRS+ System, Bio-Rad). Quantification of protein levels was performed using the Image Lab software (Bio-Rad, version 4.0). Blotting with the appropriate antibodies (Supplementary Table 5 ).
Colony formation assay
Immunohistochemistry
Freshly isolated liver tissue was washed in PBS, fixed in 4% (v/v) paraformaldehyde at 4°C degrees for at least 16-24 hours, washed in PBS, and then stored in 70% ethanol at 4°C until further processing. The tissue was dehydrated with increasing concentrations of ethanol, embedded in paraffin blocks, cut into 3/5-mm thick sections and mounted on glass slides. Sections were dewaxed and rehydrated through an ethanol scale, heated in citrate solution (BioGenex, #HK086-9K) in a water bath at 99°C for 30 minutes for antigen unmasking, washed once in water, and treated with 3% H2O2
for quenching of endogenous peroxidases. After overnight incubation at 4°C with the relevant primary antibody (Supplementary table 5 ), slides were washed twice with TBS and incubated with secondary antibodies ( Supplementary Table 5 ) for 45 minutes. The signal was revealed with DAB peroxidase substrate solution (Dako, #K3468) for 1 to 5 minutes. Slides were finally counterstained with Harris Hematoxylin (Sigma-Aldrich, #HHS80), dehydrated through alcoholic scale, and mounted with Eukitt (Bio-Optica, #09-00250).
Apoptosis was measured on FFPE liver sections derived from mice of the different genotypes with a TUNEL Assay Kit (Abcam, ab206386) according to the manufacturer's instructions, with the exception of counterstaining, which was performed with Harris Hematoxylin.
All images were acquired with the Aperio Digital Pathology Slide Scanner ScanScopeXT (Leica) and the percentage of positive cells and signal intensity were quantified with the Aperio ImageScope software (Leica). 
RNA extraction and RT-qPCR analysis
Next generation sequencing data filtering and quality assessment
RNA-seq reads were filtered using the fastq_quality_trimmer and fastq_masker tools of the FASTX-Toolkit suite (http://hannonlab.cshl.edu/fastx_toolkit/). Their quality was evaluated and confirmed using the FastQC application (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Pipelines for primary analysis (filtering and alignment to the reference genome of the raw reads) and secondary analysis (expression quantification, differential gene expression) have been integrated in the HTS-flow system 4 .
Bioinformatic and statistical analyses were performed using R with Bioconductor and comEpiTools packages 5, 6 .
RNA-seq data analysis
RNA-seq NGS reads were aligned to the mm9 mouse reference genome using the TopHat aligner (version 2.0.8) 7 with default parameters. In case of duplicated reads, only one read was kept.
Read counts were associated to each gene (based on UCSC-derived mm9 GTF gene annotations), using the featureCounts software (http://bioinf.wehi.edu.au/featureCounts/) 8 setting the options -T 2 -p -P. Differentially expressed genes (DEGs) were identified using the Bioconductor Deseq2 package 9 as genes whose q-value is lower than 0.05.
The MYC/b-catenin signature has been identified using the following criteria: 
Statistical analysis
All the experiments, were performed at least in biological triplicates. Sample size was not predetermined, but is reported in the respective Figure legends to the correspondent gene and for genes with more than 1 probe set, the mean gene expression was calculated. The downstream analysis applied is the same as for the TCGA dataset.
Oligonucleotide Primers
Primers for mRNA analysis were designed with Primer-BLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) 20 . The complete list of primers used in this study is shown in Supplementary Table 4 .
Code availability
All R scripts used in data analysis and generation of Figures are available upon request.
Data availability
RNA-seq data have been deposited in NCBI's Gene Expression Omnibus (GEO) and are accessible through GEO series accession number GSE138296. 
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